Research analysts at began coverage on shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in a research report issued on Wednesday. The brokerage set a “buy” rating and a $14.00 price target on the biopharmaceutical company’s stock. ‘s price objective indicates a potential upside of 32.70% from the company’s current price.

SCMP has been the topic of several other research reports. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Tuesday, October 17th. UBS AG decreased their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Leerink Swann began coverage on Sucampo Pharmaceuticals in a research note on Monday, August 21st. They set an “outperform” rating and a $15.00 price target on the stock. Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, B. Riley began coverage on Sucampo Pharmaceuticals in a research note on Tuesday, November 14th. They set a “buy” rating and a $14.00 price target on the stock. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $16.00.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up $0.20 during midday trading on Wednesday, reaching $10.55. The company’s stock had a trading volume of 371,355 shares, compared to its average volume of 489,092. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $17.55. The firm has a market cap of $492.01, a PE ratio of 7.23, a price-to-earnings-growth ratio of 3.14 and a beta of 1.38.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. During the same quarter in the previous year, the firm posted $0.30 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. research analysts predict that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Now Covered by Analysts at” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/19/sucampo-pharmaceuticals-inc-scmp-now-covered-by-analysts-at.html.

In other news, insider Jason Patrick Meyenburg acquired 4,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was acquired at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the acquisition, the insider now directly owns 30,228 shares in the company, valued at approximately $366,665.64. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Insiders own 4.13% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Dana Investment Advisors Inc. increased its holdings in shares of Sucampo Pharmaceuticals by 7.5% during the 3rd quarter. Dana Investment Advisors Inc. now owns 201,538 shares of the biopharmaceutical company’s stock worth $2,378,000 after buying an additional 14,089 shares during the last quarter. Argent Capital Management LLC acquired a new stake in shares of Sucampo Pharmaceuticals during the 3rd quarter worth $1,067,000. Point72 Asset Management L.P. acquired a new stake in Sucampo Pharmaceuticals in the 3rd quarter valued at $21,989,000. Royce & Associates LP increased its holdings in Sucampo Pharmaceuticals by 9.7% in the 3rd quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company’s stock valued at $13,826,000 after purchasing an additional 103,808 shares in the last quarter. Finally, Hartford Investment Management Co. acquired a new stake in Sucampo Pharmaceuticals in the 3rd quarter valued at $165,000. Institutional investors and hedge funds own 56.79% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.